Malaria Information for Health Professionals
The only FDA-approved intravenous (IV) antimalarial medication, quinidine, has been discontinued and will no longer be available. Instead, as of April 1, 2019 IV artesunate is recommended by WHO and CDC to treat patients with severe malaria. Clinicians must call CDC’s Malaria Hotline to obtain the IV artesunate. To access the CDC’s malaria hotline and receive consultations on diagnosis and management of malaria cases on a 24-hour basis, please call 770-488-7788 (from 9 a.m.-5 p.m. ET) or 770-488-7100 (after hours or on weekends and holidays). For detailed information on the criteria for IV artesunate treatment and other frequently asked questions, CDC has posted a Malaria Notice with guidance for hospitals and healthcare providers.
For more information on malaria from the CDC, please visit their website: Malaria Diagnosis & Treatment in the United States.
- Reporting Malaria (Plasmodium spp.)
Information from MDH on reporting malaria. Malaria (Plasmodium spp.) must be reported to MDH within one working day.
- Minnesota Refugee Health Provider Guide, Chapter Eight: Malaria
Malaria at a Glance - Minnesota Initial Refugee Health Assessment.
- FDA: Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria
FDA guidance for industry to reduce the risk of transfusion-transmitted malaria.
MDH staff also are available to provide clinical consultation regarding testing and diagnosis of malaria and other mosquito-transmitted diseases. Call 651-201-5414 for a clinical consultation.
See also: Information for Health Care Professionals about Mosquitoborne Diseases
Resources, slides, reporting information and other clinical information for health professionals.